Moreover, 2P23-iMab had dramatically increased potencies in inhibiting HIV-1 Env-mediated cell–cell fusion and mutant viruses with high resistance to fusion inhibitors, as well as the infections of HIV-2 and SIV isolates. This evidence concerns the gene ERVW-1 and infection.